Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma

Fig. 3

Kaplan-Meier survival analysis (log-rank test) for the entire patient cohort on the single-spot TMA. Significant survival difference between patients with HER2 expression (median OS 70.1 months (95% confidence interval 44.0–95.6 months) compared to patients without HER2 expression (median OS 24.6 months (95% confidence interval 20.7–28.5 months), p < 0.006))

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us